These data encourage the development of radiopharmaceuticals targeting the FRα or FAP to enable a broader application of radionuclide therapy to high-grade serous EOC where only FRα or FAP will be present in the tumor or the microenvironment. The gene discussed is FAP; the disease is neoplasm.